LUMICKS
LUMICKS is a life science tools company focused on immuno-oncology and molecular biology, offering Cell Avidity and Dynamic Single-Molecule technologies.
Last updated September 15, 2026
AI crawler reads
No AI crawler has read this profile since Oct 28, 2026.
Overview
LUMICKS is a next-generation life science tools company focused on enabling more efficient research, drug development, bioprocessing, bioproduction quality control, and patient treatment. Its solutions link structural and 'omics analysis to functional outcomes at molecular and cellular levels by applying and measuring forces around biological interactions. The company offers Cell Avidity, which measures the combined strength of cell-cell and cell-protein binding for immunotherapy, and Dynamic Single-Molecule technology, which reveals biomolecular interactions in real time. Its mission is to empower academic and pharmaceutical communities with cutting-edge technologies to understand mechanisms of life and disease and drive discovery of life-saving therapies.
History
LUMICKS describes its history in phases. From 2018 to 2021, it entered new markets. From 2022 onward, under the heading 'One LUMICKS', it navigated through a pandemic that greatly affected biotechs worldwide and focused on optimizing and efficiency.
Products and positioning
Next-generation life science tools company focused on enabling more efficient research, drug development, bioprocessing, bioproduction quality control, and patient treatment.
Cell Avidity
Measures the combined strength of cell-cell / cell-protein binding, generating direct, physiologically relevant measurements of binding in its full, dynamic complexity, to support progress in immunotherapy.
Dynamic Single-Molecule
Measures molecular properties and interactions while simultaneously revealing processes in real-time, unraveling dynamic interactions at the molecular level and providing direct proof of mechanisms involved.
Recent events
LUMICKS appoints Joshua Young as vice president[3]
Reported:
LUMICKS announced that it appointed Joshua Young to lead its Investor Relations, Communications and Strategy functions. Young will report to LUMICKS CEO Olivier Heyning and be based at the company's U.S. headquarters in Boston.
LUMICKS completes $93 million Series D financing[4]
Reported:
LUMICKS announced completion of a $93 million Series D preferred share financing. It said a majority of the proceeds would support growth initiatives, including expansion of research and development and commercial activities for the z-Movi Cell Avidity Analyzer.
Sources4 sources
Cite this profile: Cite the canonical profile. /brand-wiki/lumicks · Editorial policy · How profiles are compiled